Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

India: Discussion of Delhi High Court Dasatinib order – patent linkage between Indian Patent Office and Office of the Drug Controller General of India (Patent Circle) (Spicy IP) (Patent Circle) (Managing Intellectual Property)

Lescol (Fluvastatin) – US: EWHC finds sustained release Fluvastatin patent invalid on ground of obviousness: Actavis UK Ltd v Novartis AG (IPKat) (NIPC Law)

Skelaxin (Metaxalone) – US: District Court E D New York grants Eon’s motion for summary judgment, invalidating two of King Pharmaceuticals Skelaxin patents; King intends to appeal (Law360) (GenericsWeb)

WHO puts nearly $150 billion price tag on global R&D strategy for neglected diseases (Intellectual Property Watch)

Counterfeit medication, R&D financing key IP issues at WHO Board meeting (Intellectual Property Watch)

WHO members make informal progress on plan of action as executive board opens (Intellectual Property Watch)

Rumours AstraZeneca influenced Nobel Committee to award Haruld Hausen prize for medicine for discovering link between HPV and cervical cancer (Spicy IP)

Europe: ECJ hearing date fixed for reference regarding SPCs: AHP Manufacturing BV v Bureau voor de Industriële Eigendom, also operating as Octrooicentrum Nederland (SPC Blog)

India: Discussion of Delhi High Court Dasatinib order – patent linkage between Indian Patent Office and Office of the Drug Controller General of India (Patent Circle) (Spicy IP) (Patent Circle) (Managing Intellectual Property)

India: Brief note on clinical test data protection in India (IP Frontline)

United Kingdom: Bioscience Law Review article ‘Extension Granted: Gilead Obtains SPC for Combination Antiretrovirals’ (SPC Blog)

United States: Lighthouse Biosciences granted key US patent to develop diagnostics platform (Technology Transfer Tactics)

Clarinex (Desloratadine) – US: GeoPharma announces settlement of Clarinex ANDA patent litigation with Schering and Sepracor (GenericsWeb)

Cozaar (Losartan) – Netherlands: Consignment of generic Losartan manufactured by Dr Reddy’s seized during transit at Dutch port on grounds of patent infringement (Spicy IP)

Doryx (Doxycycline) – US: Warner Chilcott and Mayne Pharma file patent infringement suit to prevent Sandoz from marketing generic Doryx (Law360)

Fazaclo (Clozapine) – US: Novel lodges antitrust counterclaims against Cima Labs and Azur Pharma in FazaClo patent infringement suit (Law360)

Fortamet (Metformin) – US: Andrx, Sciele files patent infringement lawsuit against Lupin over Fortamet ANDA (Law360)

Humira (Adalimumab) – US District Court E D Texas: Centocor and New York University’s discovery motion rejected and criticised in patent infringement dispute with Abbott over Humira (Law360)

Lescol (Fluvastatin) – US: EWHC finds sustained release Fluvastatin patent invalid on ground of obviousness: Actavis UK Ltd v Novartis AG (IPKat) (NIPC Law)

Nexium (Esomeprazole) – US: AstraZeneca files patent infringement suit against Sandoz to block generic Nexium (Law360)

Singulair (Montelukast) – US: Merck strikes Teva with third Singulair suit (Law360)

Skelaxin (Metaxalone) – US: District Court E D New York grants Eon’s motion for summary judgment, invalidating two of King Pharmaceuticals Skelaxin patents; King intends to appeal (Law360) (GenericsWeb)